Clinical Research Directory
Browse clinical research sites, groups, and studies.
Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)
Sponsor: Central Hospital, Nancy, France
Summary
According to Pluvicto® indication, most of patients treated are elderly, with limited/poor venous peripheric access but they received previously chemotherapy through TIVAP and TIVAP generally stays in the body of patients when they are referred for Pluvicto® therapy. This is why TIVAP could be an interesting alternative for administering of 177Lu-PSMA-617. The aim of this study is to assess potential retention of 177Lu-PSMA-617 on TIVAP during administration through in vitro/ex vivo experimentations then in in vivo analysis.
Official title: Experience of PLUVICTO (PSMA-617 Labelled With Lutetium-177) Administration on Totally Implantable Venous Access Port (TIVAP)
Key Details
Gender
MALE
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
107
Start Date
2025-06-05
Completion Date
2025-07-30
Last Updated
2025-06-26
Healthy Volunteers
No
Conditions
Interventions
to measure the residual activity on the Totally Implantable Venous Access Port
VOI (volume of interest)TIVAP at 4 ml were drawn manually on the chamber of the TIVAP on each tomography. Blood background was determined by an VOI (volume of intesrest of Right Auricle on the right atrium. The VOIRA was automatically delineated on the CT by XXX. Standardized Uptake Value (SUV)max, SUVpeak, SUVmean were extracted from the VOIs and unilateral comparisons of superiority were performed using Wilcoxon tests. A qualitative analysis along the (TIVAP) catheter was performed: positive if an uptake was superior to the blood background and negative if any.
Locations (2)
CHRU de NANCY
Vandœuvre-lès-Nancy, France
Nuclear medicine Department CHRU de NANCY
Vandœuvre-lès-Nancy, France